What the first systematic review of CBD and canine cancer actually found

Doges Editorial · 2026-05-18 · 5 min read

Researchers at the University of Chile have published the first comprehensive systematic review of CBD's anticancer effects in dogs. The preclinical signal is consistent — and the honest picture is more nuanced than headlines suggest.

If you have had an older dog, you know the math in your gut before anyone says it out loud. You know that after about ten years, the annual vet visit changes character — that you are not just running the standard checks anymore, but paying attention to the ribcage, the weight, the energy on morning walks. Cancer is responsible for nearly half of all deaths in dogs over the age of ten. It is the most common disease of older dogs, and for most of the cancers that show up — the lymphomas, the osteosarcomas, the mast cell tumors — the treatment toolkit has not changed dramatically in decades.

Against that backdrop, a new systematic review published in the journal Frontiers in Veterinary Science is drawing attention from the veterinary research community. The study, completed by scientists at the University of Chile and released in May 2026, asked a focused question: what does the full body of existing preclinical evidence say about cannabidiol — CBD — as an anticancer agent specifically in dogs? The answer, they found, is more consistent than most people expected.

What a systematic review actually is

A systematic review is not a new experiment. The Chilean team did not put dogs in a laboratory and test CBD against tumors. What they did was go through every published study they could find — from 2015 through 2026 — that had tested cannabidiol against canine cancer cells or dog tumor models, and synthesize what those studies, taken together, show. The value of this kind of work is that it surfaces patterns invisible in any single small study and identifies where the evidence is strong, where it is thin, and where the next experiments need to happen.

The scope was wide. The review examined studies on six major canine cancer types: lymphoma, mammary cancer, glioma, prostate cancer, osteosarcoma, and urothelial carcinoma. These represent some of the most common and most devastating diagnoses a dog can receive, and they are also biologically varied enough that finding a consistent pattern across all of them is meaningful. The researchers found that pattern.

What the evidence shows

Across the studies reviewed, cannabidiol showed a consistent tendency to inhibit cancer cell growth, block cell migration (which is how cancers spread to new tissue), and trigger apoptosis — the programmed death of cancerous cells. Some studies also tested CBD in combination with conventional chemotherapy drugs, with mixed results: some combinations enhanced the effect, others reduced it, which matters for anyone thinking about CBD as an adjunct to standard treatment.

These studies consistently show that CBD exerts antiproliferative and proapoptotic effects, in some cases by modulating intracellular signaling pathways. Overall, these findings highlight the potential of CBD as an anticancer agent across different cancer types.

— University of Chile researchers, writing in Frontiers in Veterinary Science

The researchers were also careful to note what they found before 2015: almost nothing. Dog-specific CBD cancer research is a very young field. The studies that existed were scattered, used different doses, different CBD formulations, and different cell types — which makes comparing results across studies difficult. This systematic review is partly a stocktaking exercise: it maps what has been done and what needs to be standardised before results can be considered robust.

Why dogs specifically?

Dogs develop cancer at roughly the same rate as humans. Some canine cancers — particularly osteosarcoma and lymphoma — are biologically similar enough to their human counterparts that dog patients are used as natural models for oncology research, meaning treatments that work in dogs have a meaningful chance of translating to human medicine as well. Research that helps dogs helps us understand cancer in general.

But dogs also metabolize CBD differently than humans do. Their endocannabinoid systems have some similarities to ours but are not identical. What works in human cellular models — or even in rodent models — does not automatically translate to a living dog. That is why the University of Chile team focused specifically on canine studies, and why they found the literature surprisingly thin: most of the well-funded CBD cancer research has been human-focused, and the dog-specific work had never been pulled together before.

The honest caveats

The most important limitation of everything in this review is that it is almost entirely preclinical — conducted in cell cultures and laboratory assays, not in living dogs with actual tumors. A compound that kills cancer cells in a petri dish faces very different conditions inside a living body: immune response, blood flow, drug delivery, metabolic breakdown. Many promising preclinical findings have failed to replicate in clinical trials. The review makes this explicit.

Further studies are required to better elucidate the mechanisms underlying the effects of CBD and to standardize concentrations and formulations, enabling reliable, comparable results and the development of clinical studies evaluating the role of CBD in canine oncology.

— University of Chile researchers, writing in Frontiers in Veterinary Science

What the review establishes is not that CBD treats or cures cancer in dogs. What it establishes is that there is a consistent enough signal, across independent studies using different methods, to justify the next level of evidence: properly controlled clinical trials in living dogs, with standardised CBD formulations, tracked over real patient outcomes. That is still ahead. This review is the map; the territory still needs to be explored.

What's already established about safety

One finding the review is more confident about is safety. Studies on CBD in dogs consistently show it to be "safe and well-tolerated," the authors write — a threshold that any potential treatment must clear before clinical use. The FDA approved a CBD-based drug for human epilepsy in 2018, and in 2025 conditionally approved a CBD-based veterinary drug for canine noise aversion and separation anxiety. The regulatory infrastructure for CBD as a canine treatment exists. The safety data in dogs, while still being accumulated, looks encouraging.

What it means for dog owners right now

Honestly: not much, yet — if "means something" requires a clear protocol you can discuss with your vet tomorrow. No veterinary oncologist will prescribe CBD as a cancer treatment based on this systematic review, and the authors are not recommending that. What the review does is legitimise the research direction. It tells the scientific community that the signal is real and consistent enough to invest in properly structured clinical trials, which are how promising preclinical findings become actual treatments.

If those trials follow — and the review makes a strong case that they should — the landscape for canine oncology could look quite different in five years. In the meantime, the clearest early signals of cancer in older dogs come from the same place they always have: a change in appetite, a shift in energy, the way the morning walk feels a little shorter than it used to. Those signals are worth paying attention to precisely because they are early. That is what a good eye, built over years of walks together, is for.